Showing 151-160 of 160 results for "".
- Thermi Debuts Arvati Platformhttps://modernaesthetics.com/news/themi-debuts-arvati-platform/2472041/Thermi, an Almirall company, is launching Arvati, a next-generation 510K US Food and Drug Administration-cleared, true temperature-controlled radiofrequen
- RealSelf: Laser & Energy Report Identifies Key Trendshttps://modernaesthetics.com/news/realself-laser-energy-report-identifies-key-trends/2472067/Demand for fat reduction is at an all-time high, and interest in vaginal rejuvenation continues to surge. These are among key findings of the newly release RealSelf US Laser & Energy Report, released this week. First in a ne
- Cutera Marks 20 Years of Innovationhttps://modernaesthetics.com/news/cuter-marks-20-years-of-innovation/2472102/Cutera, Inc. is celebrating 20 years of best-in-class product innovation with continued commitment to the industry and its providers, marking the milestone at the Annual Meeting of the American Society for Laser Medicine and Surgery in Dallas. In conjunction with the 20th&nbs
- New AAFPRS Data: Social Media Makes Lasting Impact on Industryhttps://modernaesthetics.com/news/new-aafprs-data-social-media-makes-lasting-impact-on-industry/2472141/Like it or not, the selfie and its impact on aesthetics is here to stay, and continues to have a huge effect on how we perceive and project ourselves in front of the camera and off. This is among the main findings from the annual survey of the
- Art Lesson Teaches Plastic Surgeons Better Botox Injection Techniqueshttps://modernaesthetics.com/news/art-lesson-teaches-plastic-surgeons-better-botox-injection-techniques-facebookshare-to/2472207/A highly detailed body painting project helps plastic surgeons understand how underlying muscles contribute to facial lines and wrinkles as well as how to better treat them using botulinum toxin injections. The illustrated article, which appears in Plas
- Update: Revance Starts Phase III Studies on RT002 for Frown Lineshttps://modernaesthetics.com/news/revance-starts-phase-iii-studies-on-rt002-for-frown-lines/2472297/Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients. These pivotal trials
- Contributing Editorhttps://modernaesthetics.com/profiles/contributing-editor/7rB8NP/
- Mona Gohara, MDhttps://modernaesthetics.com/profiles/mona-gohara-md/j1DMwY/After graduating from medical school with AOA honors, Dr. Mona Gohara did her dermatology training at Yale New Haven Hospital, where she served as chief resident. Dr. Gohara continues to teach at Yale where she holds a faculty appointment as an associate clinical professor. Dr. Gohara serves as a…
- Glynis R. Ablon, MD, FAADhttps://modernaesthetics.com/profiles/glynis-r-ablon-md-faad/jVQX9E/Associate Clinical Professor U.C.L.A. Ablon Skin Institute and Research Center EMPLOYMENT: Dermatology and Cosmetic Surgery Ablon Skin Institute and Research Center: MB Studios 1600 Rosecrans, 4B, MB, CA. Aug 2001 to present Associate, Little Co. of Mary: 1010 N. Sepulveda; Manhattan Bch, CA. 9…
- Karan Lal, DO, MS, FAADhttps://modernaesthetics.com/profiles/karan-lal-do-ms-faad/L2YXnB/Originally from New York City, he grew up in Queens and attended Hunter Science High School in Manhattan. He graduated summa cum laude from the New York Institute of Technology, where he completed a rigorous seven-year accelerated combined medical program. He was selected to be an academic medical …
- Previous
- Next